Optimizing Care for Older Adults Through Thyroid Hormone Deprescribing
University of Michigan
900 participants
Dec 2, 2024
INTERVENTIONAL
Conditions
Summary
The proposed study focuses on testing a novel adapted evidence-based multilevel intervention, Deprescribing Thyroid Hormone In Older Adults (D-THIO), to support thyroid hormone deprescribing (dose de-escalation and/or discontinuation) in older adults with thyroid hormone overtreatment and/or misuse and reduce patient harm. Findings from this study will lay the groundwork for broad implementation of D-THIO and serve as a model for deprescribing inappropriate medications for other endocrine conditions and conditions with biochemical monitoring.
Eligibility
Inclusion Criteria5
- Patient Eligibility:
- age 65 years and older
- on thyroid hormone therapy and have a serum Thyroid-stimulating hormone (TSH) \<0.5 mIU/L or are on thyroid hormone therapy for an inappropriate indication
- English speaking
- without cognitive impairment
Exclusion Criteria2
- \) Patients with a diagnosis of thyroid cancer, secondary hypothyroidism, history of total thyroidectomy or hospitalization in the past 3 months will be excluded.
- Provider eligibility:
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
D-THIO consists of evidence-based pharmaceutical opinion letters to providers advising deprescribing for their patients 65 years and older with thyroid hormone overtreatment/misuse and EMPOWER ("Eliminating Medications through Patient Ownership of End Results") brochures to their patients.
American Thyroid Association \[ATA\] provider guidelines, ATA patient brochure
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06629272